Mantle Cell Lymphoma | Specialty

The mantle cell lymphoma condition center is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma. Read more at OncLive.

LV20.19 CAR T-Cell Therapy Yields 100% ORR and Manageable Toxicity in R/R MCL

April 18th 2025

On-site adaptive manufacturing of LV20.19 resulted in a high complete response rate and favorable tolerability in relapsed/refractory mantle cell lymphoma.

Ibrutinib/Lenalidomide/Rituximab Yields Long-Term Efficacy in R/R MCL

April 15th 2025

Treatment with the IR2 regimen led to durable responses that were favorable compared with those in chemotherapy-treated relapsed/refractory MCL.

BTK Inhibitor Refractoriness and Platelet Count Are Prognostic for Survival With Brexu-Cel in MCL

April 14th 2025

Patients with MCL who received real-world brexu-cel experienced lower survival when they were BTK inhibitor refractory and/or had lower platelet counts.

Dr van Meerten on the Optimal Use of Brexu-Cel in BTK Inhibitor–Naive MCL

April 11th 2025

Tom van Meerten, MD, PhD, outlines select patient subgroups with BTK inhibitor–naive relapsed/refractory MCL who may benefit from treatment with brexu-cel.

R-DA-EDOCH/R-DHAP Induction Yields Responses and MRD Negativity in Young, High-Risk MCL Population

April 8th 2025

Induction R-DA-EDOCH/R-DHAP therapy yields high rates of CR, overall response, and MRD negativity in young patients with newly diagnosed, high-risk MCL.

Dr Dreyling on the Expanding Role of BTK Inhibitors in the Treatment of MCL

April 4th 2025

Martin Dreyling, MD, discusses the expanding role of BTK inhibitors in the treatment of mantle cell lymphoma.

Single-Center Experience Highlights Utility of CD19-Directed CAR T-Cell Therapy in B-Cell Malignancies

April 3rd 2025

Real-world data with axi-cel, tisa-cel, and brexu-cel in patients with B-cell malignancies proved comparable to other experiences with cellular therapy.

Brexu-Cel Demonstrates Efficacy, Safety in Older Patients with R/R Mantle Cell Lymphoma

April 2nd 2025

Brexu-cel demonstrated clinical activity and safety in patients over 70 years of age with relapsed/refractory mantle cell lymphoma.

First-Line Acalabrutinib Plus BR Receives CHMP Recommendation for Mantle Cell Lymphoma

March 31st 2025

CHMP recommends EU approval of acalabrutinib plus chemoimmunotherapy for untreated mantle cell lymphoma.

Dr Fenske on the Benefit With Auto-HSCT in MRD-Positive Patients With MCL in First CR

March 21st 2025

Timothy S. Fenske, MD, MS, discusses survival outcomes in patients with MCL who remained MRD positive following consolidative auto-HCT.

7-Year Data Show Feasibility of Elective Treatment Interruption of Venetoclax/Ibrutinib in R/R MCL

March 14th 2025

Patients with relapsed/refractory MCL who opted for elective treatment interruptions from venetoclax/ibrutinib experienced durable responses.

Dr Phillips on Future Avenues for Improving the Management of High-Risk MCL

March 13th 2025

Tycel J. Phillips, MD, MPH, discusses the need for more large, randomized clinical trials enrolling patients with high-risk MCL.

Fixed-Duration Mosunetuzumab Demonstrates Preliminary Activity in BTK Inhibitor–Exposed R/R MCL

March 13th 2025

Single-agent mosunetuzumab generated response rates in patients with relapsed/refractory MCL who previously received a BTK inhibitor.

Dr Dreyling on the Rationale Behind the TRIANGLE Study in MCL

March 12th 2025

Martin Dreyling, MD, discusses the rationale for evaluating the addtion of ibrutinib to chemoimmunotherapy and ASCT in mantle cell lymphoma.

BOVen Regimen Is Safe and Effective in First-Line TP53-Mutated MCL

March 11th 2025

BOVen met the primary end point of 2-year PFS in a phase 2 study, displaying high response rates in treatment-naive TP53-mutated MCL.

Acalabrutinib Plus Bendamustine and Rituximab Displays Long-Term Activity in Frontline and R/R MCL

March 11th 2025

Acalabrutinib plus BR showed OS and PFS efficacy with a tolerable safety profile with long-term follow-up in first-line and R/R MCL.

Ibrutinib/Venetoclax/Obinutuzumab Controls Disease at 5 Years in Newly Diagnosed MCL

February 25th 2025

At 5 years of follow-up, sustained disease control was demonstrated with ibrutinib plus venetoclax and obinutuzumab in patients with newly diagnosed MCL.

Dr Dreyling on Safety Data With ASCT Plus Ibrutinib and Rituximab in Lower-Risk, Younger MCL

February 21st 2025

Martin Dreyling, MD, discusses updated safety results from the randomized phase 3 TRIANGLE trial in younger patients with lower-risk MCL.

Zilovertamab Vedotin Produces Activity in Heavily Pretreated R/R Mantle Cell Lymphoma

February 11th 2025

Zilovertamab vedotin generated responses and was safe in heavily pretreated relapsed/refractory mantle cell lymphoma.

Alisertib Plus Ibrutinib and Rituximab Shows Preclinical Efficacy in MCL Models

February 10th 2025

Alisertib plus ibrutinib and rituximab showed anti-tumor activity in mantle cell lymphoma in a preclinical study.